No direct shared molecular target or documented interaction between BMS-986322 and famotidine

The provided target name is a descriptive statement indicating a lack of shared molecular targets or documented pharmacological interactions between two specific compounds: BMS-986322 and famotidine. BMS-986322 is an investigational small-molecule antagonist that targets the C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5), which are involved in leukocyte trafficking and inflammatory responses (Source: Bristol Myers Squibb; ClinicalTrials.gov). Famotidine is a well-characterized histamine H2 receptor antagonist used primarily to inhibit gastric acid secretion for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcers (Source: StatPearls; PubChem). Because these drugs act on entirely different receptor families—chemokine receptors versus histamine receptors—there is no biological basis for a shared molecular target. This entry does not represent a valid therapeutic target but rather a negative finding regarding drug-drug or target-target overlap.

Not applicable as this entry describes a lack of interaction between two distinct drug targets.